Hologic (HOLX) Hits A 52-Week High: What's Driving The Stock?
Zacks Investment Research | Jan 20, 2020 07:34AM ET
On Jan 17, shares of Hologic (NASDAQ:HOLX) scaled a new 52-week high of $54.73, closing the session marginally lower at $54.32. Its impressive preliminary first-quarter fiscal 2020 earnings announcement on Jan 12 had no initial impact on the stock price. However, the stock eventually rallied 2.7% to $54.32 to close the session on Jan 17.
Strong top-line growth across core businesses, several recent launches and impressive full-year guidance prompted the rally.
Let us take a closer look at the factors driving growth.
Robust Preliminary Results
For the first-quarter of fiscal 2020, Hologic expects total revenue growth of 2.4% (up 2.8% at constant exchange rate or CER) on a year-over-year basis to $850.5 million, above the Zacks Consensus Estimate of $844.03 million. The revenue expectation also marginally exceeds the high end of the company's earlier provided guidance of $835-$850 million.
Excluding acquisitions and divestitures, revenues are estimated to increase 4.1% (suggesting a 4.6% rise at CER). According to the company, in the fiscal first quarter, revenues were strong within Surgical and Diagnostics.
Other Encouraging Factors
The company exited the fourth quarter of fiscal 2019 on a promising note, with year-over-year growth in earnings and revenues. International revenues improved 5.7% year over year during the quarter. Per management, the upside was driven by strong contributions from the Breast Health, Molecular Diagnostics and GYN Surgical businesses.
Adjusted operating margin in the quarter expanded a stupendous 419 bps.
The company announced the extension of the CE Mark for its LOCalizer radiofrequency identification tag for long-term placement in November 2019. Hologic also attained FDA approval for its 3DQuorum Imaging Technology around the same time.
Market has been upbeat about the company’s launch of Omni Lok cervical seal, the latest offering from its growing portfolio of hysteroscopic devices last October.
Meanwhile, Hologic has been having a great run on the bourses in the past year. The stock has rallied 23.2%, higher than the broader Zacks Investment Research
Get The News You Want
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.